J.W. Cole Advisors, Inc. Heron Therapeutics, Inc. Transaction History
J.W. Cole Advisors, Inc.
- $4.58 Billion
- Q2 2025
A detailed history of J.W. Cole Advisors, Inc. transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, J.W. Cole Advisors, Inc. holds 16,000 shares of HRTX stock, worth $19,040. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,000
Previous 16,000
-0.0%
Holding current value
$19,040
Previous $35,000
5.71%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding HRTX
# of Institutions
185Shares Held
130MCall Options Held
1.56MPut Options Held
27.1K-
Rubric Capital Management LP New York, NY26.7MShares$31.8 Million1.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.47MShares$10.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.33MShares$9.91 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA7.85MShares$9.34 Million0.03% of portfolio
-
Velan Capital Investment Management LP Alpharetta, GA6.99MShares$8.31 Million24.86% of portfolio
About HERON THERAPEUTICS, INC.
- Ticker HRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 118,774,000
- Market Cap $141M
- Description
- Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...